What they did

The problem is old. Once an organ leaves a donor it starts to die, and surgeons have hours. Kidneys usually sit on ice near 4 °C for about 24 hours. You cannot simply freeze them, because ice crystals shred tissue.

Powell-Palm's fix is thermodynamic rather than chemical. Keep the organ submerged in a sealed, pressure-controlled chamber and you can hold it a few degrees below zero without ice forming, and without antifreeze chemicals (cryoprotectants) that would need their own approval. The device is deliberately plain: a hermetically sealed box with a clear lid and a sensor. He calls it "low-tech high science."

To test it, the team removed one kidney from each pig and flushed it with the standard transplant solution. Some kidneys went on ice for 2 or 24 hours (the clinical baseline). Others went into the device for 24, 48, or 72 hours. Each stored kidney was then transplanted back into its original donor pig, and that pig's remaining healthy kidney was removed, so the animal had to survive on the reconditioned organ alone. A genuine test, not a bench readout.

What they found

• Kidneys supercooled for 72 hours were working normally within about 10 days of transplant. Slower than a 2-hour ice kidney, but faster than one kept on ice for 24 hours.
• The 48- and 72-hour organs performed similarly. Seventy-two hours is triple today's clinical standard.
• Over 30 days the pigs grew about 30%, and the lone kidney nearly doubled in size to keep up.
• One pig was followed for 200 days; its kidney still looked healthy at the end.
• In preliminary work, kidneys held up to 120 hours looked healthy, though those were not transplanted.
• The chamber is small enough that the team drove supercooled kidneys across the country in the back of a Kia Sorento. Air travel is untested.

Strengths

• The right animal model. Pig kidneys are close to human size and physiology, and this was a life-supporting autotransplant, the demanding version of the test.
• Long follow-up. Two hundred days in one animal, and 30-day function across the group, is more than a "the organ pinked up" snapshot.
• No cryoprotectants. Skipping antifreeze chemicals removes a toxicity question and a regulatory hurdle, which is why the team hopes for a faster FDA path.
• Independent corroboration of the direction. A separate Toronto group published a peer-reviewed porcine kidney subzero autotransplant study in the American Journal of Transplantation in early 2026, with no ice damage and no mortality at 7 days. Different method, same encouraging direction.
• Real theory underneath. The isochoric approach is not new hand-waving; Powell-Palm and Rubinsky have a decade of published thermodynamics behind it, including supercooled human cardiac microtissue work.

Weaknesses

• Not peer reviewed. This is a conference presentation. Numbers, animal counts, and statistics have not been vetted or published. Treat every figure as provisional. Promising, unverified
• Small and unstated N. The article gives no sample size. The headline-grabbing results (200 days, 120 hours) may rest on a single animal each.
• Autotransplant sidesteps rejection. Putting a kidney back in its own donor removes the immune matching that dominates real transplantation. This tests preservation, not the full clinical gauntlet.
• Financial stake. The lead investigator owns the company selling the device. Not disqualifying, but it is exactly the setup where independent replication matters most.
• "Landmark" is the journalist's frame. The quote marks in the headline are doing work. Pigs are not people, days are not the years that a transplant needs to last, and a Kia is not a transatlantic flight.

Perfusion: the commercial present Mature

The baseline for decades has been static cold storage: flush the kidney with a cold solution and put it on ice near 4 °C. Cheap, simple, and good for roughly 24 hours before injury builds up. Machine perfusion replaces the ice bath with a pump that circulates fluid through the organ's vessels, and it comes in two temperatures.

Hypothermic perfusion (cold, often oxygenated, branded HOPE) keeps the organ cold but continuously flushed. For kidneys this is the mature device space: Organ Recovery Systems (LifePort, which the company says has preserved more than 275,000 kidneys since 2003) and XVIVO (Kidney Assist) lead, with randomized evidence going back to 2009 showing less delayed graft function than plain ice.

Normothermic perfusion (warm oxygenated blood, ~37 °C) takes the opposite view: keep the organ alive and metabolically active, which also lets you test it before committing. TransMedics (Organ Care System, for heart, lung, and liver) and OrganOx (metra, an FDA-approved liver device) lead here. Paragonix (SherpaPak) is a smart cooler, controlled cold without a pump, and Bridge to Life (VitaSmart) is a cleared liver HOPE device. The whole tier still lives inside roughly the 24-hour window. The win is organ quality and viability assessment, not time.

Supercooling: the near-term stretch Emerging

Hold the organ below 0 °C without letting ice form, and hours become days. This is where Powell-Palm's BioChoric sits. Its main company is Sylvatica Biotech, which grew out of the Uygun lab at Massachusetts General Hospital and the Sebastian Giwa orbit of preservation ventures, and works mostly on livers using supercooling and "partial freezing," with published human-liver supercooling and multi-day rat-liver survival. Days of storage with comparatively modest engineering. The catch: the striking results are still largely preclinical.

Cryopreservation: the actual endgame Horizon

Freeze the organ solid for indefinite banking, the way we already bank sperm, eggs, and embryos, and transplantation stops being a frantic logistics problem and becomes an inventory problem. Two approaches compete. Vitrification plus nanowarming loads the organ with cryoprotectants so it turns to glass rather than ice, then rewarms it evenly using iron-oxide nanoparticles excited by a magnetic field to avoid the cracking that killed earlier attempts. This is the Bischof and Uygun academic program at the University of Minnesota and MGH, which sustained a rat on a frozen-and-rewarmed kidney in 2023 and is now scaling the physics toward human-organ volumes. X-Therma uses synthetic peptoid antifreeze for ice-free vitrification, aimed squarely at kidney, with DARPA and NIH backing. Both are preclinical for whole human organs, but this is the difference between "days" and "shelf life."